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http://dx.doi.org/10.1016/j.jmii.2012Background/Purpose: There are only three case reports of adult patients with spontaneous
Pantoea agglomerans bacteremia in the English literature. The aim of this study was to inves-
tigate clinical and microbiologic characteristics patients of P agglomerans bacteremia.
Methods: We studied all adult patients with P agglomerans bacteremia at a medical center
from 2000 to 2010. The isolates were identified using two commercial identification systems.
Results: Of the 18 patients identified, 72% (n Z 13) had active gastroesophageal disease
treated with antacids. Two-thirds of patients had indwelling central lines and advanced
cancers. None of the removed catheter tips yielded P agglomerans and line persistence was
not associated with adverse outcomes. Initial disease severity was low, hypotension was
uncommon and no patient died of bacteremia. Recurrence of bacteremia occurred in one
patient with deep-seated infection. 16srRNA gene sequencing identified only half of the
isolates as P agglomerans. The remaining nine isolates were Enterobacter species for six, Pan-
toea ananatis for two, and Exiguobacterium profundum for one. There were no significant
differences between the characteristics of the subgroup molecularly identified as P agglomer-
nas and the overall group characteristics. Eleven (61%) of the 18 isolates were susceptible to
cefazolin, six (33%) susceptible to fosfomycin (MIC  64 mg/ml). Two isolates had colistin MICs
 4 mg/ml.
Conclusion: Bacteremia caused by P agglomerans is associated with gastroesophageal reflux
disease and receipt of antacids. 16srRNA gene sequencing should not be used as the sole basis
for its identification and we have highlighted the need for another molecular-based techniqueof Internal Medicine, Far Eastern Memorial Hospital, New Taipei City 220, Taiwan.
ail.com (C.-H. Liao).
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Pantoea agglomerans, previously known as Erwinia herbi-
cola or Enterobacter agglomerans, is a facultative anaer-
obic gram-negative bacillus frequently associated with
plants. It is the most clinically significant species of the
highly diverse genus of Pantoea, yet its role as a human
pathogen continues to be questioned due to infrequent
reports of spontaneously occurring P agglomerans infec-
tions and uncertainties in taxonomic identification.1e3
P agglomerans has been isolated from the blood in the
context of outbreaks caused by the use of contaminated
intravenous products and medical equipment.4e6 However,
there are only three reports of adults with sporadic
bacteremia (not outbreak-related) due to P agglomerans in
the English literature.7e9 Given the commercial and scien-
tific interests in this species as a biocontrol agent for
a variety of plant diseases10,11 as well as a source of an
anticancer lipopolysaccharide with immune enhancing
activity,12,13 its clinical significance is of relevance not only
to physicians, but also to scientists and stakeholders. In the
past, few clinical reports have incorporated 16S rRNA gene
sequence information for the identification of P
agglomerans.1,2
In this study, we investigated clinical and microbiologic
characteristics patients of sporadic P agglomerans bacter-
emia at our university hospital in Taiwan over the last
decade.
Materials and methods
Hospital setting
The National Taiwan University Hospital, is a 2500-bed,
academically affiliated medical center providing both
primary and tertiary care in Taipei, Taiwan. All patients
seen at the hospital with clinical specimen positive cultures
for Pantoea species from January 2000 to December 2010
were retrieved from our microbiology laboratory database.
Of these patients, we selected cases whose blood cultures
were positive for P agglomerans.
Bacterial identification
In this study, identification of the preserved isolates of
P agglomerans was performed by using two commercial
identification systems: Enterotube II (Becton Dickinson
Diagnostic Systems, Sparks, MD, USA) and Phoenix Identifi-
cation System PMIC/ID-30 (Becton Dickinson Diagnostic
Systems).
The 16S rRNA gene sequencing analysis was also per-
formed for all preserved Pantoea agglomerans isolates.14
The amplification products, obtained by polymerase chain
reaction (PCR) with primers 8FPL (5’-AGAGTTTGATCCTGGCTCAG-3’) and 1492RPL (5’-GGTTACCTTGTTACGA
CTT-3’),were sequenced, and the sequenceswerecompared
to known 16S rRNA gene sequences in the GenBank database
of theNational Centre for Biotechnology Informationbyusing
theBasic Local Alignment SearchTool (BLAST) algorithm.The
species with the best match and their accession numbers
were obtained.14
Antimicrobial susceptibilities
Antimicrobial susceptibilities were determined by the agar
dilution method for ampicillin, amoxicillineclavulanic acid,
cefazolin, cefmetazole, cefotaxime, ceftazidime,
piperacillin-tazobactam, ertapenem, imipenem, cipro-
floxacin, gentamicin, amikacin, colistin, and fosfomycin
according to the Clinical and Laboratory Standards Institute
(CLSI) criteria for Enterobacteriaceae.15 There were no
minimum inhibitory concentrations (MICs) interpretive
criteria of colistin for Enterobacteriaceae.15 Tigecycline
MICs were determined by broth microdilution and inter-
preted by the guidelines recommended by the U.S. Food
and Drug Administration for Enterobacteriaceae (suscep-
tible, MICs of 2 mg/ml). Quality control tests were per-
formed using Escherichia coli ATCC 25922, and
Pseudomonas aeruginosa ATCC 27853.
Clinical characteristics of patients
A retrospective review of the medical records of cases with
blood isolates unanimously identified as P agglomerans by
biochemical methods was performed using a standard
computerized form. Baseline demographic and clinical
characteristics were recorded. The composite measure for
chronic health status was measured by the Charlson’s
comorbidity index.16 Initial disease severity was assessed
using the Pitt bacteremia score.17 Outcome measures
included time to defervescence, time to microbiological
eradication, and time to hospital discharge.
To investigate the clinical implications of possible reso-
lution problems at the species level with 16S rRNA gene
sequencing data, we analyzed clinical or microbiological
differences between patients whose strains were typed as P
agglomerans by 16S rRNA gene sequence compared to the
entire study population.
Results
Overall, a total of 307 clinical isolates from 237 patients,
including 105 (34.2%) blood isolates from 59 (24.9%)
patients were identified as Pantoea species by traditional
biochemical tests during the 10-year study period (Fig. 1).
Since taxonomic misidentifications are common for
P agglomerans, we re-tested the archived blood isolates.
Phenotypically, there were 25 patients with 28 isolates
Figure 1. Flow diagram of cases identification and
enrollment.
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isolates of P agglomerans identified by Enterotube II and 22
patients with 24 isolates Phoenix system. Good agreement
was observed between the two commercial systems, with
all 22 patients identified to be P agglomerans by the
automated Phoenix system also being identified as P
agglomerans by the Enterotube II. All patients contributed
one isolate of P agglomerans each. Only one patient
contributed three blood isolates collected at different
times spanning a period of 1 year.
Of the 22 individuals with blood isolates that were
unanimously phenotypically P agglomerans, we excluded
four pediatric cases and analyzed the eighteen patients
aged 18 years and above with P agglomerans bacteremia.
These patients were disseminated in space and time
(see Table 1). Nine (50%) patients were subsequently
identified as P agglomerans by 16S rRNA gene sequencing,
seven with 99%e100% maximal identity, and two with 94%e
96% similarity. The closest matches on GenBank, all with at
least 99% maximal identity, for the remaining nine patients
were Enterobacter species for four patients (33.3%),
Enterobacter hormaechei for two patients (22.2%), Pantoea
ananatis for another two patients (22.2%), and Exiguo-
bacterium profundum for one patient (5.6%).
The baseline demographics and clinical characteristics
of these eighteen patients are summarized in Table 1. The
patient and microbiological characteristics of the subgroup
molecularly identified as P agglomerans are compared to
the entire cohort in Tables 2 and 3.
Of the 18 patients, 11 (61.1%) were male and the median
age was 57 years of age. Approximately two-thirds of
patients had underlying malignancy; six (33.3%) with
advanced solid organ malignancy (all stage IV disease) and
five (27.8%) with hematologic malignancies. Thirteen
patients (72.2%) had symptoms of gastroesophageal reflux
disease and were receiving antacids at onset of bacter-
emia. Twelve patients (66.6%) had indwelling central
venous catheters at bacteremia onset, with an even
distribution between nontunneled (n Z 6) and tunneled
lines with reservoir ports (n Z 6). The median Charlson’s
comorbidity index was moderately high at four (range,
1e9). ABO blood-group A (44.4%), rather than blood GroupO (33.3%) was the most frequent blood group among these
patients. In the general Taiwanese population, these
proportions are reversed with Group O (44%) being more
common than Group A (26%).18
The majority of cases were classified as primary blood-
stream infections (66.6%) CDC/NHSN criteria for infections
in the acute care settings were followed.19 There were
three cases of bacteremia secondary to intra-abdominal
infections (16.7%), two cases secondary to soft tissue
infections (11.1%), and one secondary to pneumonia (5.6%).
The median onset of bacteremia was 1 week following
admission, but ranged from the day of admission to seven
weeks later. Initial disease severity as assessed by the Pitt
Bacteremia Score was low, with a median score of 1.
Indeed, eight patients had Pitt scores of zero; five had
transient hypotension (27.8%) and only one patient required
intensive care. Fever (72.2%) and gastrointestinal symp-
toms (44.4%) were common as were the laboratory findings
of anemia (77.8%) and abnormal leucocyte count with an
equal likelihood of leucopenia (38.9%) or leukocytosis
(38.9%). Most patients (55.6%, nZ 10) had two or more sets
of blood cultures positive for P agglomerans. Seven patients
had P agglomerans growing in only one of two sets of blood
cultures and one patient had only one set of blood culture
drawn in total.
Among the 18 P agglomerans isolates (only the first pre-
treatment isolate from the patient with recurrent bacter-
emia was tested), 10 (56%) isolates were susceptible to
ampicillin, 11 (61%) susceptible to cefazolin (MIC 2 mg/
ml), and six (33%) susceptible to fosfomycin (MIC  64 mg/
ml) (Table 4). Two isolates had colistin MICs of 4 mg/ml (4
and >128 mg/ml, respectively). Thus, the vast majority of
patients (88.9%) received effective empirical antibiotics
and treatment was successful in all cases both in terms of
clinical and bacteriological cure. There were two unrelated
in-hospital deaths, one due to progressive lymphoma (4
months after P agglomerans bacteremia) and the other due
to subsequent sepsis due to methicillin-resistant Staphylo-
coccus aureus (MRSA) infection (3 months later). There was
only one case with recurrent P agglomerans bacteremia
after an interval of 11 months, in whom the focus was
septic arthritis.
In the subgroup analysis of patients whose 16S rRNA gene
sequencing was most closely matched to P agglomerans, we
found no significant differences between the clinical and
microbiological characteristics of this subgroup compared
to the overall group (Table 3). Of note, in one individual
with more than one blood isolates available for 16S rRNA
gene sequencing, the accession numbers and molecular
identities using this gene were incongruous within the same
host and did not match antimicrobial susceptibility patterns
(data not shown). Particularly, the patient with recurrent
bacteremic septic arthritis had three sequential blood
isolates matched to three different accession numbers; the
first isolate was obtained in December 2004, susceptible to
all antibiotics tested and identified as P agglomerans
(FJ756348.1), the second blood isolate was alternatively
identified as Enterobacter species in late November 2005
(EU078564.1) but shared acquired resistance to ampicillin
and cefazolin with the last isolate (obtained 5 days later in
early December 2005) identified as 94% P agglomerans
(FJ999930.1). Although pulse-field gel electrophoresis
Table 1 Clinical and microbiological characteristics of 18 adult patients with sporadic Pantoea agglomerans bacteremia
Year Age M/F Underlying Comorbidities Onset day Infection Site Medication history Clinical presentation Concomitant
pathogen
16S rRNA ID,
(accession number)
Outcomes
1 2000 66 F Stroke, heart failure,
diabetes mellitus
1 SSTI Nil Left leg necrotizing
fasciitis
Group B
Streptococcus
99% E. hormaechei
(EF428236.2)
Died 82
days later
2 2001 56 M Lymphoma stage III, GERD 20 Primary BSI Antacid,
chemotherapy
Epigastralgia, fever
after endoscopy
Nil 99% Enterobacter
spp. (FN908870.1)
Discharge
3 2001 57 M Depression, GERD 1 Primary BSI Antacid Headache and fever
due to neurosyphilis
Nil 99% P agglomerans
(HM130693.1)
Discharge
4 2003 55 M Alcoholic liver cirrhosis,
Child C, GERD
1 IAI Antacid Abdominal pain
and diarrhea
Nil 99% E profundum
(HM584043.1)
Discharge
5 2003 74 M Hepatocellular carcinoma
stage IV,
diabetes mellitus
21 Primary BSI Nil Out-of-hospital
cardiac arrest
Nil 99% P ananatis
(GU339282.1)
Discharge
6 2003 73 F Depression 5 Primary BSI Antacid Suicide attempt with
corrosive esophagitis
P aeruginosa
K oxytoca
99% E hormaechei
(EF428236.2)
Discharge
7 2004 32 F Cervical cancer stage IV,
HBV active carrier
1 IAI Antacid,
chemotherapy
Seizure and chills due
to brain metastases
Nil 94% P agglomerans
(AY941841.1)
Discharge
8 2004 74 M Lymphoma stage IV,
heart failure
24 Primary BSI Antacid,
chemotherapy
Fever and chills after
chemotherapy
Nil 99% P agglomerans
(GU477762.1)
Died 118
days later
9 2004 39 M Depression, septic arthritis 21 Septic arthritis Antacid Right hip pain Candida albicans
A baumannii
96% P agglomerans
(FJ756348.1)
Discharge
10 2005 48 F Polymyositis,
diabetes mellitus
54 Primary BSI Antacid, steroid Meningism due to
cryptococcosis
Nil 99% P agglomerans
(FJ999930.1)
Discharge
11 2005 74 F Acute myeloid leukemia 8 Primary BSI Antacid,
chemotherapy
Post-chemotherapy
fever, abdominal pain
Nil 99% Enterobacter
spp. (AM396909.1)
Discharge
12 2006 46 M Acute hepatitis
secondary to HBV
12 IAI Nil Jaundice, vomiting,
abdominal fullness
Nil 99% P ananatis
(DQ777968.1)
Discharge
13 2006 43 M Esophageal cancer IV,
aortic pseudoaneurysm
3 Primary BSI Antacid,
chemotherapy
Post-chemotherapy
fever and dysphagia
Nil 99% Enterobacter
spp. (FN908870.1)
Discharge
14 2007 72 F Biliary pancreatitis, GERD 1 IAI Antacid Epigastralgia S parasanguis 100% P agglomerans
(HM130696.1)
Discharge
15 2008 74 F Lymphoma stage IV,
Grave’s disease, GERD,
HBV/HCV co-infection
12 Primary BSI Antacid,
steroid
Fever after biopsy
of abdominal tumor
S maltophilia 99% P agglomerans
(FJ593000.1)
Discharge
16 2009 57 M Hypertension, MGUS CKD
stage IV, gout
22 Primary BSI Steroid Fever after dialysis
for acute renal failure
Nil 99% P agglomerans
(GU991862.1)
Discharge
17 2009 67 M Bladder cancer stage IV 1 LRTI Nil Fever, vomiting,
aspiration pneumonia
Nil 99% Enterobacter
spp.(FN908870.1)
Discharge
18 2010 52 M Breast cancer
stage IV, GERD
1 Primary BSI Antacid,
chemotherapy
Chills after systemic
chemotherapy
A baumannii 99% P agglomerans
(JN585671.1)
Discharge
BSI Z primary bloodstream infection including catheter associated bacteremia; CKD Z chronic kidney disease; GERD Z gastroesophageal reflux disease; HBV/HCV Z hepatitis B virus/
hepatitis C virus; ID Z identification; IAI Z intra-abdominal infection; LRTI Z lower respiratory tract infection; M/F Z male/female; MGUS Z monoclonal gammopathy of unknown
significance; SSTI Z skin and skin structure infection.
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Table 2 Demographics of patients with Pantoea agglomerans bacteremia
Total patients
(n Z 18)
P agglomerans
by 16S rRNA (n Z 9)
Other species by
16S rRNA (n Z 9)
Age, median years (range) 57.0 (32.0e74.9) 57.0 (32.0e74.4) 66.3 (43.9e74.9)
Men, % (n) 61.1 (11) 55.6 (5) 66.7 (6)
Average body mass index, median kg/m2 (range) 22.8 (11.7e33.9) 22.3 (11.7e33.9) 23.1 (18.6e26.8)
Admission to onset, median days (range) 6.5 (0e54) 12 (0e54) 5.0 (0e21)
ABO blood group, % (n)
A blood type 44.4 (8) 44.4 (4) 44.4 (4)
B blood type 11.1 (2) 22.2 (2) 0
O blood type 33.3 (6) 22.2 (2) 44.4 (4)
Underlying disease, % (n)
Peptic ulcer disease 72.2 (13) 66.7 (6) 77.8 (7)
Active malignancy 61.1 (11) 66.7 (6) 55.6 (5)
Hematologic cancers 27.8 (5) 33.3 (3) 22.2 (2)
Solid organ cancers 33.3 (6) 33.3 (3) 33.3 (3)
Chronic viral hepatitis 44.4 (8) 33.3 (3) 55.6 (5)
Cerebrovascular accident 22.2 (4) 11.1 (1) 33.3 (3)
Diabetes mellitus 16.7 (3) 11.1 (1) 22.2 (2)
Congestive heart failure 16.7 (3) 11.1 (1) 22.2 (2)
Autoimmune or connective tissue disease 11.1 (2) 22.2 (2) 0
Chronic obstructive pulmonary disease 5.6 (1) 11.1 (1) 0
End-stage renal disease 5.6 (1) 11.1 (1) 0
Charlson’s index, median (range) 4 (1-9) 3 (1-8) 4 (1-9)
Risk for Pantoea agglomerans bacteremia, % (n)
Receipt of antacid 72.2 (13) 88.9 (8) 55.6 (5)
Receipt of steroid 33.3 (6) 55.6 (5) 11.1 (1)
Chemotherapy within 4 wks 33.3 (6) 33.3 (3) 33.3 (3)
In-situ central venous catheter 66.7 (12) 77.8 (7) 55.6 (5)
Tunneled CVC 33.3 (6) 22.2 (2) 44.4 (4)
Non-tunneled CVC 33.3 (6) 55.6 (5) 11.1 (1)
Sites of infection, % (n)
Primary bloodstream infection 66.7 (12) 77.8 (7) 55.6 (5)
Catheter-associated 44.4 (8) 66.7 (6) 22.2 (2)
Intra-abdominal infection 16.7 (3) 11.1 (1) 22.2 (2)
Soft-tissue infection 11.1 (2) 0 22.2 (2)
Pneumonia 5.6 (1) 0 11.1 (1)
Bacteremia caused by P agglomerans 191would be necessary to confirm these isolates were of the
same strain, reinfection at each point with a different strain
of P agglomerans was less likely due to the rarity of this
pathogen in an otherwise immunocompetent host in whom
the primary site of infection was the same throughout.Discussion
In this single-center cohort study of 18 adults with
P agglomerans bacteremia, we demonstrated that
P agglomerans is a pathogen of low virulence even in
immunocompromised hosts. Our report is unique for col-
lecting the largest series of P agglomerans bacteremic
cases that have occurred outside the context of iatrogenic
outbreaks and neonatology.4e6,20
Two of the three published adult cases of P agglomerans
septicemia have occurred in debilitated patients; one with
colon cancer and the other with acute myeloid leukemia.7,9Consistent with these reports, the majority of our patients
also suffered from advanced malignancy (Table 2).
In addition, we found a strong association between
spontaneously occurring bacteremia and upper gastroin-
testinal symptoms alongside antacid receipt. Given that the
ABO blood Group A is well known to be associated with
certain gastrointestinal tract disorders including esopha-
geal adenocarcinoma21 and gastric carcinoma associated
with pernicious anemia,22 overrepresentation of blood
Broup A individuals among this cohort (44.4%) compared
with the general Taiwanese population (26%)17 and the
prominence of anemia (77.8%), reinforces the association
between gastroesophageal disease and transient bacter-
emia with P agglomerans.
As Pantoea species are commonly found on plants, they
may be introduced by ingestion of vegetables or fruits, with
the opportunity for gastrointestinal translocation in the
presence of gastroesophageal mucosal lesions and/or in the
absence of protective stomach acidity. Whether blood
group A phenotypes reflect a genetic susceptibility to P
Table 3 Clinical presentations, laboratory findings, and outcome of patients with Pantoea agglomerans bacteremia
Total patients
(n Z 18)
P agglomerans
by 16S rRNA (n Z 9)
Other species by
16S rRNA (n Z 9)
Symptoms and signs
Pitt bacteremia score, median (range) 1 (0e5) 1 (0e5) 1 (0e4)
Temperature, median (range), C 38.7 (36.7e39.8) 38.2 (36.7e39.8) 38.9 (36.6e40.4)
Mean arterial pressure, median (range) 79.8 (35.7e102.0) 77.0 (35.7e101.7) 81.3 (43.3e102)
Fever, % (n) 72.2 (13) 66.7 (6) 77.8 (7)
Gastrointestinal symptoms, % (n) 44.4 (8) 22.2 (2) 66.7 (6)
Shock, % (n) 27.8 (5) 33.3 (3) 22.2 (2)
Laboratory findings at bacteremia onset, % (n)
Leukocytosis 38.9 (7) 44.4 (4) 33.3 (3)
Leukopenia 38.9 (7) 33.3 (3) 44.4 (4)
Thrombocytopenia 50.0 (9) 22.2 (2) 77.8 (7)
Anemia 77.8 (14) 66.7 (6) 88.9 (8)
Two or more sets of positive cultures 55.6 (10) 55.6 (5) 55.6 (5)
Drug susceptibility, % (n)
Ampicillin resistant 50.0 (9) 33.3 (3) 66.7 (6)
Treatment and clinical outcome, % (n)
Defervescence within 48 hrs 84.6 (11/13) 83.3 (5/6) 85.7 (6/7)
Recurrence of bacteremiaa 5.6 (1) 11.2 (1) 0
Initial appropriate antibiotic treatment 88.9 (16) 88.9 (8) 88.9 (8)
Antibiotic duration, median d (range) 14 (7 - 25) 14 (9 e 18) 14 (7 e 25)
Clinical treatment success 100 (18) 100 (9) 100 (9)
Length of stay, median d (range) 29.5 (6-211) 42 (13 e 211) 28 (6-79)
28-d mortality 0 0 0
Hospital mortality 11.1 (2) 5.6 (1) 5.6 (1)
a Bacteremia recurred one month after completion of antibiotic treatment for initial bacteremia.
192 A. Cheng et al.agglomerans infection directly and not by way of associa-
tion with gastric intestinal metaplasia is presently specu-
lative and warrants further elucidation.
By contrast to previous reports of sporadic P agglom-
erans bacteremia secondary to compartmentalized infec-
tion, e.g., cases of septic arthritis, synovitis,Table 4 In vitro susceptibility of 18 isolates of Pantoea agglom
MIC
Range
Ampicillin 0.03e128
Amoxicillin-clavulanate 0.03e8
Cefazolin 0.25e64
Cefmetazole 0.06e16
Cefotaxime 0.03e0.5
Ceftazidime 0.03e1
Piperacillin-tazobactam 0.03e4
Ertapenem 0.03e0.06
Imipenem 03-0.5
Ciprofloxacin 0.03-0.25
Gentamicin 0.25e1
Amikacin 0.5e2
Colistin 0.25 to >128
Fosfomycin 16 to >256
Tigecycline 0.03e0.25
a Minimum inhibitory concentrations (MICs) of the 18 isolates to tigec
other 13 agents were determined by the agar dilution method.
b MIC susceptibility breakpoint is not available.osteomyelitis, endophthalmitis and peritonitis related to
penetrating injuries with vegetative material such as plant
thorns,23e26 the majority of our cases had primary blood-
stream infections; by definition not secondary to a local-
ized foci. Although often associated with the presence of
intravascular catheters, these infections did not appear toerans to 15 antimicrobial agentsa
(mg/ml) Susceptible (%)
MIC50 MIC90
8 128 10 (56)
4 4 18 (100)
2 8 11 (61)
4 8 18 (100)
0.12 0.5 18 (100)
0.25 0.5 18 (100)
2 4 18 (100)
0.03 0.03 18 (100)
0.12 0.5 18 (100)
0.03 0.03 18 (100)
0.25 0.5 18 (100)
1 2 18 (100)
0.5 1 bd
128 >256 6 (33)
0.12 0.12 18 (100)
ycline were determined by the broth microdilution method and to
Bacteremia caused by P agglomerans 193be directly related to the catheter by tip culture or
differential time to positivity. This is in line with the prior
reported case with acute myeloid leukemia, whose
infection also did not appear to be line-related.9
Furthermore, persistence of the catheter was not associ-
ated with adverse outcomes or relapses. Therefore, we
propose the gastrointestinal tract rather than the intra-
venous catheter to be the more common portal of entry in
these patients.
As far as we know, there is only one case of P agglom-
erans pneumonia in a heart-lung transplant recipient in the
English literature.27 Likewise the respiratory tract was the
least common site of infection in our series. Although more
sporadic infections were reported to be community
acquired, the aforementioned heart-lung transplant recip-
ient was a case of nosocomial pneumonia. Similarly, one-
half of the patients in this current series acquired
P agglomerans infection after the first week of hospitali-
zation and were not classically cases from the community.
Hence, Pantoea species may be ubiquitous in both the
community and hospital environment.
Resolution problems at the genus and/or species level
with 16S rRNA gene sequencing data have been reported by
phylogenetic scientists for Pantoea.28 In this clinical study,
we agree that the 16S rRNA gene does not offer additional
discriminatory value for classifying this species although
previous studies have attempted to use it as a confirmatory
identification tool.7,28 However, a limitation of this study
was the lack of type strains of Pantoea agglomerans for
alignment comparisons with our isolates’ 16s rRNA gene
sequences.
The miscellaneous genotypes found for the phenotypi-
cally homogenous group suggests that currently,
P agglomerans may represent a complex of closely related
organisms rather than a single organism. The amount of
diversity within P agglomerans and its population structure
remains unclear.1 Another possibility is that there is intra-
genomic heterogeneity of the 16S rRNA gene among Pan-
toea species that would preclude the use of this technology
for species identification.28 However, due to the lack of
major inter- and intra-individual differences regardless of
16S rRNA gene-based identification, further delineation by
sophisticated molecular methods may not be so much
a clinical priority as an academic interest.
Like other published cases, we showed that P agglom-
erans is not infrequently isolated in conjunction with
established pathogens in polymicrobial infections.
P agglomerans is known to compete successfully with the
indigenous flora of a variety of microenvironments, and it is
suggested that this may occur through the production of
potent antimicrobial agents.2,13,29 Since P agglomerans is
often isolated from patients with cancers, we were curious
to whether this immunomodulatory agent also has anti-
cancer properties. Literature review revealed that immu-
nopotentiator from P agglomerans 1 (IP-PA1) ameliorates
chemotherapy-induced immunosuppression.29,30 In vitro
experiments showed that IP-PA1 activated nuclear factor-
kappa B (NF-kB) and ameliorated doxorubicin induced
growth inhibition of macrophages30 whilst in vivo experi-
ments showed that IP-PA1 improved survival of melanoma-
bearing, doxorubicin treated mice.30Hence from the antibacterial and anticancer molecules
that P agglomerans secretes, this species may not be simply
the villainous emerging opportunistic human pathogen that
previous case reports have depicted. Rather it may be
a symbiotic commensal or innocent bystander since serious
morbidity and mortality appears not a common feature in
our cohort.
This “friendor foe”distinctioncarriesnotonly therapeutic
but also important biosafety implications. In the United
States, Pantoea species are largely regarded as “friends” and
are currently approved by the U.S. Environmental Protection
Agency (EPA) to be used as microbial pesticides. In Europe,
this species have currently been classified as biosafety level
two organisms.2 However due to the resoundingly assuring
goodprognosis associatedwith these infections,wehopethat
our cohort study and literature review will help dispel
excessive concerns and broaden perspectives on both the
potential harm and benefits of P agglomerans.
In conclusion, this report indicated a high association
between spontaneous P agglomerans bacteremia and upper
gastrointestinal disease, antacid therapy, and ABO blood
Group A. However, comparison data of appropriate control
populations, including all patients with bacteremia, are
needed to make these conclusions. The prognosis is excel-
lent even in immunocompromised hosts. 16S rRNA gene
sequencing should not be used as the sole basis for its
identification and we have highlighted the need for another
molecular-based technique to conclusively characterize
P agglomerans.References
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